Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
New Horizons in Dyslipidaemia 2026
Added: 4 weeks ago Source:  Radcliffe CVRM
Radcliffe Cardiology has announced New Horizons in Dyslipidaemia 2026, a live virtual event on 12 February 2026 (14:00–17:55 GMT) that will convene twelve international leaders to examine how lipid management is evolving, and where current practice continues to fall short.Despite the availability of highly effective lipid-lowering therapies, residual cardiovascular risk remains common. At the… View more

Guidelines & Statements

Prevention & Chronic Conditions
Author(s): Stephen Nicholls Added: 5 months ago
ESC Congress 2025 - Pooled MACE Analysis of obicetrapib shows reductions in cardiovascular events and consistent reductions in LDL cholesterol and LP(a).Prof Stephen Nicholls (Monash Victorian Heart Institute, AU) joins us to discuss findings from a pooled major adverse cardiovascular events (MACE) analysis of obicetrapib, examining early signals of cardiovascular benefit in patients with… View more

Prevention & Chronic Conditions
Familial Hypercholesterolaemia in the Asia-Pacific Region
Author(s): Satoshi Honda , Jonathan Yap , Ivan Olegario , et al Added: 4 months ago

Prevention & Chronic Conditions
AHA 25: CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3
Author(s): Stephen Nicholls Added: 3 months ago
AHA Scientific Sessions 2025 - Phase 1 results show the CRISPR-Cas9 gene editing therapy is a safe treatment option targeting ANGPTL3 in patients with lipid disorders.Prof Stephen Nicholls (Monash Victorian Heart Institute, Clayton, AU) joins us to share results from a first-in-human phase 1 trial investigating a one-time infusion of CTX310, a CRISPR-Cas9 gene editing therapy, at different doses… View more

Prevention & Chronic Conditions
Transforming Outcomes with Lipid Clinics in Malaysia: Enablers and Barriers for the Implementation of Multidisciplinary Approach Clinics for the Management of Dyslipidaemia
Author(s): Azhari Rosman , Ahmad Khairuddin Mohamed Yusof , Hafidz Abd Hadi , et al Added: 1 month ago

Prevention & Chronic Conditions
William Herrington
Research Area(s) / Expertise: Job title: Professor of Trials and Epidemiology of Kidney Disease
Professor William Herrington is an Honorary Consultant Nephrologist at Oxford Kidney Unit and the Professor of Trials and Epidemiology of Kidney Disease at the Nuffield Department of Population Health, University of Oxford.Prof Herrington earned his MD from the University of Cambridge in 2013, focusing on the impact of lowering LDL cholesterol on stroke in chronic kidney disease.He has previously… View more
Dr Oliver Weingärtner currently works at University Hospital Jena. As a certified interventional cardiologist and angiologist he has been trained inInternal Medicine, Cardiology, Angiology and Intensive Care MedicineLipidologist (DGFF®) Dr Weingärtner is the current President of the German Society of Lipidology. His research interests focus on cholesterol metabolism and cardiovascular risk. View more
AHA 23: 3 Trials That Will Change My Practice
Author(s): Purvi Parwani Added: 2 years ago
AHA 23 — Dr Purvi Parwani, cardiologist and multimodality imager, and director of the Women's Heart Clinic at Loma Linda University Health in the US, spotlights three game-changing late-breaking science trials from the AHA Scientific Sessions. Discover the trials anticipated to reshape clinical practices as Dr Parwani shares her insights.Trials discussed in detail include:POP-HT: Cardiac… View more

Guidelines & Statements

Prevention & Chronic Conditions
ESC 25: The NEWTON-CABG CardioLink-5 Study
Author(s): Subodh Verma Added: 5 months ago
ESC Congress 2025 - NEWTON-CABG finds evolocumab with regular statin therapy did not improve vein graft patency after coronary artery bypass graft (CABG) surgery in the short-term.Dr Subodh Verma and Dr Lawrence Leiter (University of Toronto, Toronto, CA) join us to discuss findings from NEWTON-CABG CardioLink-5 (NCT03900026). The investigator-initiated multicenter, randomised, placebo-controlled… View more

Intervention
AHA 25 Late-breaking Discussion: The VESALIUS-CV Trial
Author(s): Erin A Bohula , Harriette Van Spall Added: 2 months ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9… View more

MI/ACS

Prevention & Chronic Conditions